Mostrar el registro sencillo del ítem

dc.contributor.authorManso, Luis
dc.contributor.authorHernando, Cristina
dc.contributor.authorGalán, María
dc.contributor.authorOliveira, Mafalda
dc.contributor.authorCabrera, Miguel A
dc.contributor.authorBratos, Raquel
dc.contributor.authorRodríguez, César A
dc.contributor.authorRuiz-Borrego, Manuel
dc.contributor.authorBlanch, Salvador
dc.contributor.authorLlombart-Cussac, Antonio
dc.contributor.authorDelgado-Mingorance, Juan I
dc.contributor.authorÁlvarez-Busto, Iñaki
dc.contributor.authorGallegos, Isabel
dc.contributor.authorGonzález-Cortijo, Lucía
dc.contributor.authorMorales, Serafín
dc.contributor.authorAguirre, Elena
dc.contributor.authorHernando, Blanca A
dc.contributor.authorBallesteros, Ana
dc.contributor.authorAlés-Martínez, José E
dc.contributor.authorREBOREDO RENDO, CRISTINA 
dc.contributor.authorOltra, Amparo
dc.contributor.authorGonzález-Cao, María
dc.contributor.authorSantisteban, Marta
dc.contributor.authorMalón, Diego
dc.contributor.authorEcheverría, Isabel
dc.contributor.authorGarcía-Garre, Elisa
dc.contributor.authorVega, Estela
dc.contributor.authorServitja, Sònia
dc.contributor.authorAndrés, Raquel
dc.contributor.authorRobles, Carlos E
dc.contributor.authorLópez López, Rafael 
dc.contributor.authorGalve, Elena
dc.contributor.authorEcharri, María J
dc.contributor.authorLegeren, Marta
dc.contributor.authorMoreno, Fernando
dc.date.accessioned2022-03-16T08:38:35Z
dc.date.available2022-03-16T08:38:35Z
dc.date.issued2020
dc.identifier.issn0960-9776
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/33242755es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16272
dc.description.abstractBACKGROUND: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR(+)/HER2(-)) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from February 2015 to November 2017. PATIENTS AND METHODS: Patient data were collected retrospectively from 35 hospitals in Spain. Patients with HR(+)/HER2(-) mBC who had progressed on >/=4 treatments for advanced disease were eligible. RESULTS: A total of 219 patients received palbociclib in combination with aromatase inhibitors (110; 50.2%), fulvestrant (87; 39.7%), tamoxifen (8; 3.6%) or as single agent (10; 4.6%). Mean age of the patients was 58 years; 31 patients (16.1%) were premenopausal and 162 (83.9%) were postmenopausal at the beginning of treatment with palbociclib. Patients had received a median of 3 previous lines of endocrine therapy (ET) for advanced disease. Real-world tumor response (rwTR) and clinical benefit rate were 5.9% (n = 13) and 46.2% (n = 101), respectively. The median real world progression-free survival (rwPFS) was 6.0 months (95% CI 5.7-7.0) and the median overall survival was 19.0 months (95% CI 16.4-21.7). Subgroup analysis revealed a significant difference in median rwPFS in patients treated with palbociclib plus fulvestrant depending on the duration of prior treatment with fulvestrant monotherapy (>6 versus </=6 months; HR 1.93, 95% CI 1.37-2.73, p < 0.001). The most frequently reported toxicities were neutropenia, asthenia, thrombopenia and anemia. CONCLUSIONS: Palbociclib can be an effective and safe treatment option in patients with heavily pretreated endocrine-sensitive mBC, especially in those with longer PFS to previous ET.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titlePalbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)en
dc.typeJournal Articlees
dc.authorsophosManso, Luis;Hernando, Cristina;Galán, María;Oliveira, Mafalda;Cabrera, Miguel A;Bratos, Raquel;Rodríguez, César A;Ruiz-Borrego, Manuel;Blanch, Salvador;Llombart-Cussac, Antonio;Delgado-Mingorance, Juan I;Álvarez-Busto, Iñaki;Gallegos, Isabel;González-Cortijo, Lucía;Morales, Serafín;Aguirre, Elena;Hernando, Blanca A;Ballesteros, Ana;Alés-Martínez, José E;Reboredo, Cristina;Oltra, Amparo;González-Cao, María;Santisteban, Marta;Malón, Diego;Echeverría, Isabel;García-Garre, Elisa;Vega, Estela;Servitja, Sònia;Andrés, Raquel;Robles, Carlos E;López, Rafael;Galve, Elena;Echarri, María J;Legeren, Marta;Moreno, Fernando
dc.identifier.doi10.1016/j.breast.2020.11.005
dc.identifier.pmid33242755
dc.identifier.sophos36151
dc.journal.titleBREASTes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médicaes
dc.relation.publisherversionhttps://www.thebreastonline.com/article/S0960-9776(20)30211-3/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUACes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number54.es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International